Head and Neck Cancer News and Research

RSS

Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).

Analysis stresses importance of multidisciplinary approach to cancer in the elderly

New research showing that almost half of 13,000 patients with head and neck cancers had other health-related problems at the same time is one of the presentations in a special session at the 31st conference of the European Society for Radiotherapy and Oncology (ESTRO 31) today.

14 May 2012

Advaxis commences enrollment in ADXS-HPV Phase 1/2 study for head and neck cancer

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that two patients have been enrolled into REALISTIC, a Phase 1/2 study being sponsored by Cancer Research UK (CRUK) to investigate the use of ADXS-HPV for the treatment of HPV positive head and neck cancer. HPV is associated with 40-70% of head and neck cancers.

8 May 2012

OncoSec reports positive interim data from ElectroChemotherapy Phase IV head and neck cancer study

OncoSec Medical Inc., which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, today announced positive interim analysis of data from 81 subjects in a Phase IV study of primary and locally recurrent squamous cell carcinoma of the head and neck (HNSCC) treated with OMS ElectroChemotherapy in Europe.

23 Apr 2012

Patients with head and neck cancer can benefit from swallowing exercises

Mount Sinai School of Medicine researchers have found that targeted swallowing exercises can help alleviate swallowing dysfunction - a debilitating side effect in people undergoing chemoradiation therapy (CRT) for head and neck cancer.

20 Apr 2012

ESTRO 31 and the World Congress of Brachytherapy to take place from May 9-13

ESTRO 31 and the World Congress of Brachytherapy will combine to feature new research results in clinical and basic radiobiology, physics and brachytherapy, presented by top doctors and scientists from all over the world working together for the benefit of cancer patients.

19 Apr 2012

Access reports positive interim results from MuGard Phase 4 clinical trial in oral mucositis

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology and oncology supportive care, announced interim results from its ongoing MuGard Phase 4 clinical trial in oral mucositis.

18 Apr 2012

Idera commences IMO-3100 Phase 2 clinical trial for psoriasis

Idera Pharmaceuticals, Inc. today announced the treatment of the first patient in a Phase 2 clinical trial of IMO-3100, the Company's lead Toll-like receptor (TLR) inhibitor for the treatment of autoimmune diseases, in patients with moderate to severe plaque psoriasis.

18 Apr 2012

UTMDACC to offer free head and neck cancer screening exams on April 27

The University of Texas MD Anderson Cancer Center will offer free head and neck cancer screening exams to the public on Fri., April 27 from 10 a.m. to 3 p.m. in the Cancer Prevention Center at the Cancer Prevention Building, 1155 Pressler Street, Floor 2.

16 Apr 2012

Combination of carboplatin, paclitaxel and RT3D shows promise against head and neck cancer

A naturally-occurring harmless human virus may be able to boost the effects of two standard chemotherapy drugs in some cancer patients, according to early stage trial data published in Clinical Cancer Research.

4 Apr 2012

Navidea announces FDA extension of Lymphoseek PDUFA date by three months

Navidea Biopharmaceuticals, Inc. today announced that yesterday it received notification from the United States Food and Drug Administration (FDA) that the Prescription Drug User Fee Act (PDUFA) date for 99m-Tc-Tilmanocept, has been modified to September 10, 2012, a 90-day extension from the initial PDUFA date of June 10th.

4 Apr 2012

CYP1B1 protein may be a potential target for intervention in head and neck cancer

Squamous cell carcinoma of the head and neck-which typically arises from thin, flat cells that line moist surfaces inside the mouth, nose and throat-is the sixth most common type of cancer worldwide, and it has a relatively low five-year survival rate and a high recurrence rate.

2 Apr 2012

Clinical data for cabozantinib to be presented at ASCO annual meeting

Exelixis, Inc. announced today that its lead compound, cabozantinib, will be the subject of nine separate data presentations at the upcoming Annual Meeting of the American Society of Clinical Oncology.

2 Apr 2012

RT3D may boost effects of two standard chemotherapy drugs in head and neck cancer patients

2 Apr 2012

Aurora-A protein plays an important role in head and neck cancer

Researchers at Fox Chase Cancer Center in Philadelphia have found that a protein associated with other cancers appears to also be important in head and neck cancer, and may consequently serve as a good target for new treatments. The findings will be reported at the AACR Annual Meeting 2012 on Sunday, April 1.

2 Apr 2012

HPV-related head and neck cancer on the rise among middle-aged white men

Research led by Lauren Cole, a public health graduate student, and Dr. Edward Peters, Associate Professor of Public Health and Director of the Epidemiology Program at LSU Health Sciences Center New Orleans, reports that the incidence of head and neck cancer has risen at sites associated with Human Papilloma Virus (HPV) infection, with the greatest increase among middle-aged white men.

30 Mar 2012

OncoSec to present data from head and neck cancer studies at two upcoming conferences

OncoSec Medical Incorporated., which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that the company has been selected to present data from its Phase III and IV head and neck cancer studies at two upcoming conferences.

23 Mar 2012

U.S. to launch graphic anti-smoking warnings

The United States Government is starting a major new effort to cut the country's smoking rate by showing graphic images of people who have sustained life-altering health problems after smoking for years.

18 Mar 2012

Sosei initiates SO-1105 Phase I trial in oropharyngeal candidiasis

Sosei Group Corporation, the biopharmaceutical company, today announces that its wholly owned Japanese subsidiary, Sosei Co., Ltd., has initiated a Japanese Phase I trial for SO-1105 for the treatment of oropharyngeal candidiasis.

8 Mar 2012

Inovio's SynCon vaccine for HPV types 6 and 11 induces CD8+ T cells in mice

Inovio Pharmaceuticals, Inc. announced today that its SynCon therapeutic vaccine for human papillomavirus (HPV) types 6 and 11, which are associated with head & neck cancers and genital warts, among other conditions, induced strong antigen-specific CD8+ T cells in mice.

5 Mar 2012

Proceeds from Polo Under the Palms in Sarasota to benefit MD Anderson Cancer Center

Polo mallets and palm trees take center stage as Polo Under the Palms returns to Sarasota, Fla., March 24. Proceeds from the second annual competition benefit The University of Texas MD Anderson Cancer Center.

2 Mar 2012

Head and Neck Cancer News and Research

Analysis stresses importance of multidisciplinary approach to cancer in the elderly

Advaxis commences enrollment in ADXS-HPV Phase 1/2 study for head and neck cancer

OncoSec reports positive interim data from ElectroChemotherapy Phase IV head and neck cancer study

Patients with head and neck cancer can benefit from swallowing exercises

ESTRO 31 and the World Congress of Brachytherapy to take place from May 9-13

Access reports positive interim results from MuGard Phase 4 clinical trial in oral mucositis

Idera commences IMO-3100 Phase 2 clinical trial for psoriasis

UTMDACC to offer free head and neck cancer screening exams on April 27

Combination of carboplatin, paclitaxel and RT3D shows promise against head and neck cancer

Navidea announces FDA extension of Lymphoseek PDUFA date by three months

CYP1B1 protein may be a potential target for intervention in head and neck cancer

Clinical data for cabozantinib to be presented at ASCO annual meeting

RT3D may boost effects of two standard chemotherapy drugs in head and neck cancer patients

Aurora-A protein plays an important role in head and neck cancer

HPV-related head and neck cancer on the rise among middle-aged white men

OncoSec to present data from head and neck cancer studies at two upcoming conferences

U.S. to launch graphic anti-smoking warnings

Sosei initiates SO-1105 Phase I trial in oropharyngeal candidiasis

Inovio's SynCon vaccine for HPV types 6 and 11 induces CD8+ T cells in mice

Proceeds from Polo Under the Palms in Sarasota to benefit MD Anderson Cancer Center

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News